MCF Advisors LLC Cuts Stock Position in Humana Inc. (NYSE:HUM)

MCF Advisors LLC trimmed its position in shares of Humana Inc. (NYSE:HUM) by 3.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,916 shares of the insurance provider’s stock after selling 155 shares during the period. MCF Advisors LLC’s holdings in Humana were worth $1,243,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Pzena Investment Management LLC raised its stake in shares of Humana by 538.7% during the second quarter. Pzena Investment Management LLC now owns 2,318,347 shares of the insurance provider’s stock worth $866,250,000 after acquiring an additional 1,955,375 shares in the last quarter. Davis Selected Advisers raised its position in Humana by 16.1% in the 2nd quarter. Davis Selected Advisers now owns 2,311,362 shares of the insurance provider’s stock worth $863,640,000 after purchasing an additional 321,233 shares during the period. Marshall Wace LLP lifted its stake in Humana by 118.9% in the second quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock worth $532,564,000 after purchasing an additional 774,085 shares during the last quarter. Legal & General Group Plc boosted its position in Humana by 2.1% during the second quarter. Legal & General Group Plc now owns 1,183,985 shares of the insurance provider’s stock valued at $442,396,000 after buying an additional 24,842 shares during the period. Finally, Ontario Teachers Pension Plan Board boosted its position in Humana by 11,647.2% during the first quarter. Ontario Teachers Pension Plan Board now owns 1,059,478 shares of the insurance provider’s stock valued at $367,342,000 after buying an additional 1,050,459 shares during the period. Institutional investors own 92.38% of the company’s stock.

Humana Stock Up 0.8 %

NYSE HUM traded up $2.15 during trading hours on Friday, reaching $260.73. 1,824,348 shares of the company’s stock traded hands, compared to its average volume of 3,859,698. The firm has a market cap of $31.39 billion, a PE ratio of 18.60, a PEG ratio of 2.04 and a beta of 0.50. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.66 and a quick ratio of 1.66. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $527.18. The firm has a 50-day simple moving average of $306.51 and a 200 day simple moving average of $336.35.

Humana (NYSE:HUM) last released its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.89 by $1.07. The firm had revenue of $29.54 billion during the quarter, compared to analyst estimates of $28.52 billion. Humana had a net margin of 1.53% and a return on equity of 16.12%. The business’s revenue was up 10.4% on a year-over-year basis. During the same period last year, the business earned $8.94 earnings per share. Sell-side analysts anticipate that Humana Inc. will post 16.06 EPS for the current fiscal year.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.36%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana’s dividend payout ratio (DPR) is 25.25%.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on HUM. Jefferies Financial Group lowered Humana from a “buy” rating to a “hold” rating and lowered their target price for the company from $519.00 to $253.00 in a research note on Monday, October 7th. Barclays lowered their price objective on Humana from $364.00 to $250.00 and set an “equal weight” rating for the company in a research report on Thursday, October 10th. Piper Sandler cut shares of Humana from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $392.00 to $274.00 in a report on Thursday, October 3rd. UBS Group lowered their price target on shares of Humana from $380.00 to $250.00 and set a “neutral” rating for the company in a report on Friday, October 4th. Finally, Royal Bank of Canada dropped their target price on shares of Humana from $400.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. One equities research analyst has rated the stock with a sell rating, nineteen have assigned a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Humana presently has a consensus rating of “Hold” and an average price target of $315.33.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.